! K: D5 @! c# W' z- m9 N, V
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:5 j* }$ U9 S/ c) l, G
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.6 [, v S0 U+ A8 p, x http://www.ncbi.nlm.nih.gov/pubmed/229681841 w' x: i* L( ~2 T